Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

Kari R. Irvine, Ronald S. Chamberlain, Eliza P. Shulman, Deborah R. Surman, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P

Original languageEnglish (US)
Pages (from-to)1595-1601
Number of pages7
JournalJournal of the National Cancer Institute
Volume89
Issue number21
StatePublished - Nov 5 1997
Externally publishedYes

Fingerprint

Galactosidases
Synthetic Vaccines
Vaccination
Fowlpox virus
Cowpox virus
Antigens
Bacterial DNA
Cancer Vaccines
Vaccinia virus
Histocompatibility Antigens Class II
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Organism Cloning
Colon
Plasmids
Vaccines
Neoplasm Metastasis
Carcinoma
Lung
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Irvine, K. R., Chamberlain, R. S., Shulman, E. P., Surman, D. R., Rosenberg, S. A., & Restifo, N. P. (1997). Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. Journal of the National Cancer Institute, 89(21), 1595-1601.

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. / Irvine, Kari R.; Chamberlain, Ronald S.; Shulman, Eliza P.; Surman, Deborah R.; Rosenberg, Steven A.; Restifo, Nicholas P.

In: Journal of the National Cancer Institute, Vol. 89, No. 21, 05.11.1997, p. 1595-1601.

Research output: Contribution to journalArticle

Irvine, KR, Chamberlain, RS, Shulman, EP, Surman, DR, Rosenberg, SA & Restifo, NP 1997, 'Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors', Journal of the National Cancer Institute, vol. 89, no. 21, pp. 1595-1601.
Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. Journal of the National Cancer Institute. 1997 Nov 5;89(21):1595-1601.
Irvine, Kari R. ; Chamberlain, Ronald S. ; Shulman, Eliza P. ; Surman, Deborah R. ; Rosenberg, Steven A. ; Restifo, Nicholas P. / Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. In: Journal of the National Cancer Institute. 1997 ; Vol. 89, No. 21. pp. 1595-1601.
@article{dcd24df535af4369b6f898de4a8402ad,
title = "Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors",
abstract = "Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P",
author = "Irvine, {Kari R.} and Chamberlain, {Ronald S.} and Shulman, {Eliza P.} and Surman, {Deborah R.} and Rosenberg, {Steven A.} and Restifo, {Nicholas P.}",
year = "1997",
month = "11",
day = "5",
language = "English (US)",
volume = "89",
pages = "1595--1601",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "21",

}

TY - JOUR

T1 - Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

AU - Irvine, Kari R.

AU - Chamberlain, Ronald S.

AU - Shulman, Eliza P.

AU - Surman, Deborah R.

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

PY - 1997/11/5

Y1 - 1997/11/5

N2 - Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P

AB - Background: The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). Methods: Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial β-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded β-galactosidase-vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to β- galactosidase. Results: Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P

UR - http://www.scopus.com/inward/record.url?scp=0030663697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030663697&partnerID=8YFLogxK

M3 - Article

C2 - 9362157

AN - SCOPUS:0030663697

VL - 89

SP - 1595

EP - 1601

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 21

ER -